Related Experiment Video
Updated: Jun 7, 2025
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
Therapeutic advances in the targeting of ROR1 in hematological cancers
Adrian-Bogdan Tigu1, Raluca Munteanu1, Cristian Moldovan1
1Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Cluj Napoca, Romania.
Abstract:
Receptor tyrosine kinases (RTKs) are key cell surface receptors involved in cell communication and signal transduction, with great importance in cell growth, differentiation, survival, and metabolism. Dysregulation of RTKs, such as EGFR, VEGFR, HER2 or ROR, could lead to various diseases, particularly cancers. ROR1 has emerged as a promising target in hematological malignancies. The development of ROR1 targeted therapies is continuously growing leading to remarkable novel therapeutical approaches using mAbs, antibody-drug conjugates, several small molecules or CAR T cells which have shown encouraging preclinical results. In the hematological field, mAbs, small molecules, BiTEs or CAR T cell therapies displayed promising outcomes with the clinical trials data encouraging the use of anti-ROR1 therapies. This paper aims to offer a comprehensive analysis of the current landscape of ROR1-targeted therapies in hematological malignancies marking the innovative approaches with promising preclinical and clinical. Offering a better understanding of structural and functional aspects of ROR1 could lead to new perspectives in targeting a wide spectrum of malignancies.
Insights
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) targeted therapies show promise for treating blood cancers. Novel treatments including monoclonal antibodies and CAR T cells are advancing, with clinical trials demonstrating encouraging outcomes for anti-ROR1 strategies.
Area of Science:
- Oncology
- Molecular Biology
- Immunotherapy
Background:
- Receptor tyrosine kinases (RTKs) regulate crucial cellular functions, and their dysregulation is linked to cancer development.
- ROR1, a specific RTK, is implicated in various diseases, particularly hematological malignancies, making it a significant therapeutic target.
Purpose of the Study:
- To provide a comprehensive analysis of current ROR1-targeted therapies for hematological malignancies.
- To highlight innovative therapeutic approaches and their preclinical and clinical outcomes.
Main Methods:
- Review of current literature on ROR1-targeted therapies.
- Analysis of preclinical and clinical trial data for various therapeutic modalities.
Main Results:
- ROR1-targeted therapies, including monoclonal antibodies (mAbs), antibody-drug conjugates, small molecules, and CAR T cells, show promising preclinical results.
- Clinical trials in hematological malignancies indicate encouraging outcomes for anti-ROR1 therapies, including mAbs, small molecules, and CAR T cells.
Conclusions:
- ROR1 is a validated and promising therapeutic target in hematological malignancies.
- Ongoing development of ROR1-targeted therapies offers new perspectives for treating a range of cancers.
